Cargando…

Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study

AIM: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A(1)chieve study. MATERIALS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Wangnoo, Subhash Kumar, Ghosal, Samit, Akhtar, Shahid, Shetty, Raman, Tripathi, Sudhir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171898/
https://www.ncbi.nlm.nih.gov/pubmed/25285292
http://dx.doi.org/10.4103/2230-8210.139239
_version_ 1782335969109737472
author Wangnoo, Subhash Kumar
Ghosal, Samit
Akhtar, Shahid
Shetty, Raman
Tripathi, Sudhir
author_facet Wangnoo, Subhash Kumar
Ghosal, Samit
Akhtar, Shahid
Shetty, Raman
Tripathi, Sudhir
author_sort Wangnoo, Subhash Kumar
collection PubMed
description AIM: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A(1)chieve study. MATERIALS AND METHODS: Indian patients with T2D switching from pre-study IGlaror NPH insulin to IDet were included. Safety and effectiveness outcomes were evaluated by the physicians in local clinical settings. RESULTS: A total of 102 patients switched from IGlar to IDet (GLA group) and 39 patients switched from NPH insulin to IDet (NEU group). At baseline, the mean glycated hemoglobin A(1c) (HbA(1c)) levels were 9.9 ± 1.8% in the GLA group and 9.1 ± 1.2% in the NEU group. No serious adverse drug reactions, serious adverse events, or major hypoglycemic events were reported in either group throughout the study. At baseline and Week 24, 11.8% and 7.5% of patients, respectively, reported overall hypoglycemic events in the GLA group. No hypoglycemic events were reported at Week 24 in the NEU group. At Week 24, the mean HbA(1c) levels were 7.6 ± 0.9% in the GLA group and 7.3 ± 0.7% in the NEU group. The mean fasting plasma glucose, postprandial plasma glucose and quality of life also appeared to improve over 24 weeks. CONCLUSION: Switching to IDet therapy from IGlar and NPH insulin was well-tolerated and appeared to be associated with improved glycogenic control in Indian patients.
format Online
Article
Text
id pubmed-4171898
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41718982014-10-03 Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study Wangnoo, Subhash Kumar Ghosal, Samit Akhtar, Shahid Shetty, Raman Tripathi, Sudhir Indian J Endocrinol Metab Original Article AIM: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A(1)chieve study. MATERIALS AND METHODS: Indian patients with T2D switching from pre-study IGlaror NPH insulin to IDet were included. Safety and effectiveness outcomes were evaluated by the physicians in local clinical settings. RESULTS: A total of 102 patients switched from IGlar to IDet (GLA group) and 39 patients switched from NPH insulin to IDet (NEU group). At baseline, the mean glycated hemoglobin A(1c) (HbA(1c)) levels were 9.9 ± 1.8% in the GLA group and 9.1 ± 1.2% in the NEU group. No serious adverse drug reactions, serious adverse events, or major hypoglycemic events were reported in either group throughout the study. At baseline and Week 24, 11.8% and 7.5% of patients, respectively, reported overall hypoglycemic events in the GLA group. No hypoglycemic events were reported at Week 24 in the NEU group. At Week 24, the mean HbA(1c) levels were 7.6 ± 0.9% in the GLA group and 7.3 ± 0.7% in the NEU group. The mean fasting plasma glucose, postprandial plasma glucose and quality of life also appeared to improve over 24 weeks. CONCLUSION: Switching to IDet therapy from IGlar and NPH insulin was well-tolerated and appeared to be associated with improved glycogenic control in Indian patients. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4171898/ /pubmed/25285292 http://dx.doi.org/10.4103/2230-8210.139239 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Wangnoo, Subhash Kumar
Ghosal, Samit
Akhtar, Shahid
Shetty, Raman
Tripathi, Sudhir
Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
title Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
title_full Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
title_fullStr Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
title_full_unstemmed Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
title_short Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
title_sort clinical experience of switching from glargine or neutral protamine hagedorn insulin to insulin detemir in type 2 diabetes: observations from the indian cohort in the a(1)chieve study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171898/
https://www.ncbi.nlm.nih.gov/pubmed/25285292
http://dx.doi.org/10.4103/2230-8210.139239
work_keys_str_mv AT wangnoosubhashkumar clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT ghosalsamit clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT akhtarshahid clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT shettyraman clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT tripathisudhir clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy